Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.52) per share for the quarter.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA traded up $0.30 during midday trading on Monday, reaching $4.90. 303,135 shares of the stock were exchanged, compared to its average volume of 867,764. Olema Pharmaceuticals has a 12 month low of $2.86 and a 12 month high of $16.62. The business has a 50-day simple moving average of $4.27 and a two-hundred day simple moving average of $6.29. The company has a market capitalization of $334.70 million, a price-to-earnings ratio of -2.24 and a beta of 2.03.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on OLMA shares. JPMorgan Chase & Co. dropped their price target on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, March 28th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Monday, April 28th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.